Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen's Q3 Revenues, Profit Spur 10 Percent Stock Surge

NEW YORK (GenomeWeb News) - Invitrogen’s share price jumped 10 percent today after the firm released third-quarter results that showed a double-digit increase in revenues and a swing from a loss to a profit.
 
The firm reported after the close of the market yesterday that its third-quarter revenues had spiked up 11 percent to $315 million and that last year’s losses had been turned to a $31 million profit.
 
The stock was up $8.34 at $91.41 in late afternoon trading today.
 

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.